Shopping Cart
Remove All
Your shopping cart is currently empty
BCR-ABL-IN-13
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T212936 Copy Product Info
Purity: 99.92%
🥰Excellent
BCR-ABL-IN-13 is a dual c-Src and Abl inhibitor, with a Ki value of 0.55 μM against c-Src, 0.10 μM against wild-type Abl, and 0.40 μM against the AblT315I mutant. BCR-ABL-IN-13 exerts competitive/mixed-type inhibitory effects on wild-type Abl, and non-competitive inhibitory effects on the drug-resistant AblT315I mutant. BCR-ABL-IN-13 is used in chronic myeloid leukemia research models to study kinase inhibition profiles, resistance-associated Abl mutations, and signaling pathway modulation in oncogenic tyrosine kinase systems.
BCR-ABL-IN-13
Cas No. 607702-99-8
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | - | In Stock | |
| 5 mg | $89 | - | In Stock | |
| 10 mg | $139 | - | In Stock | |
| 25 mg | $278 | - | In Stock | |
| 50 mg | $446 | - | In Stock | |
| 100 mg | $712 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.92%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | BCR-ABL-IN-13 is a dual c-Src and Abl inhibitor, with a Ki value of 0.55 μM against c-Src, 0.10 μM against wild-type Abl, and 0.40 μM against the AblT315I mutant. BCR-ABL-IN-13 exerts competitive/mixed-type inhibitory effects on wild-type Abl, and non-competitive inhibitory effects on the drug-resistant AblT315I mutant. BCR-ABL-IN-13 is used in chronic myeloid leukemia research models to study kinase inhibition profiles, resistance-associated Abl mutations, and signaling pathway modulation in oncogenic tyrosine kinase systems. |
| Targets & IC50 | Abl:0.10 μM (Ki), c-Src:0.55 μM (Ki), Abl (T315I):0.40 μM (Ki) |
| In vitro | Methods：The effects of BCR-ABL-IN-13 on mouse myeloid clones expressing imatinib-sensitive and drug-resistant Bcr-Abl were detected.
Results：BCR-ABL-IN-13 exerted potent cytotoxicity against all the above cell lines [1]. |
| Molecular Weight | 363.41 |
| Formula | C16H11F2N3OS2 |
| Cas No. | 607702-99-8 |
| Smiles | O=C(NC1=NN=C(S1)SCC2=CC=C(F)C=C2)C3=CC=C(F)C=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: BCR-ABL-IN-13 in vitro | BCR-ABL-IN-13 formula | BCR-ABL-IN-13 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.